Literature DB >> 22346418

Immunotherapy of airborne tuberculosis in mice via the lung-specific delivery of cytokines.

M Denis1, E Ghadirian.   

Abstract

The immunotherapeutic potential of interleukin-2 (IL-2), tumour necrosis factor alpha (TNFα) and interferon gamma (IFN-γ) administered by aerosol was examined on mice infected with Mycobacterium tuberculosis by the aerogenic route. Infection of balb/c mice with 10(4) colony forming units (cfu) of M tuberculosis led to death of all mice at day 35 post infection after progressive microbial growth in the lungs. Aerosolization of IL-2 (100 μg per mouse) did not promote an increase in resistance to tuberculosis, as seen by growth of M tuberculosis in the lungs. Administration of IFN-γ or TNFα (100 μg) by the aerosol route led to a significant reduction in microbial growth in the lungs and a 100% survival of infected mice at day 60. Similarly, aerosolization of TNFα and IFN-γ combined led to a very high degree of tuberculostatic activity in the lungs of infected animals, but not superior to that seen with either cytokine alone. Administration of similar amounts of cytokines by repeated intraperitoneal infusions led to a very marginal improvement in mouse resistance. These results suggest that localized cytokine administration may be beneficial in the treatment of lung diseases.

Entities:  

Keywords:  Cytokines; Mycobacterium tuberculosis

Year:  1993        PMID: 22346418      PMCID: PMC3250802          DOI: 10.1155/1993/954372

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN: 1180-2332


  23 in total

1.  The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis.

Authors:  I M Orme
Journal:  J Immunol       Date:  1987-01-01       Impact factor: 5.422

Review 2.  Biological response modifiers: the new immunotherapy.

Authors:  K A Foon
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

3.  Toxicity of human recombinant interleukin-2 in rats. Pathologic changes are characterized by marked lymphocytic and eosinophilic proliferation and multisystem involvement.

Authors:  T D Anderson; T J Hayes
Journal:  Lab Invest       Date:  1989-03       Impact factor: 5.662

4.  Granulocyte-macrophage colony-stimulating factor restricts growth of tubercle bacilli in human macrophages.

Authors:  M Denis; E Ghadirian
Journal:  Immunol Lett       Date:  1990-06       Impact factor: 3.685

5.  The effect of gamma-interferon during Mycobacterium bovis (BCG) infection in athymic and euthymic mice.

Authors:  D K Banerjee; A K Sharp; D B Lowrie
Journal:  Microb Pathog       Date:  1986-04       Impact factor: 3.738

6.  Successful treatment with aerosolized pentamidine of Pneumocystis carinii pneumonia in rats.

Authors:  R J Debs; W Blumenfeld; E N Brunette; R M Straubinger; A B Montgomery; E Lin; N Agabian; D Papahadjopoulos
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

7.  Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes.

Authors:  M Malkovský; B Loveland; M North; G L Asherson; L Gao; P Ward; W Fiers
Journal:  Nature       Date:  1987 Jan 15-21       Impact factor: 49.962

8.  Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis.

Authors:  F Y Liew; C Parkinson; S Millott; A Severn; M Carrier
Journal:  Immunology       Date:  1990-04       Impact factor: 7.397

9.  Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection.

Authors:  A Nakane; T Minagawa; K Kato
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

10.  The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2.

Authors:  G Kaplan; R Kiessling; S Teklemariam; G Hancock; G Sheftel; C K Job; P Converse; T H Ottenhoff; M Becx-Bleumink; M Dietz
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.